Skip to main content
Top
Published in: European Journal of Pediatrics 10/2016

Open Access 01-10-2016 | Original Article

Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease

Authors: Daniël R. Hoekman, Kay Diederen, Bart G. P. Koot, Merit M. Tabbers, Angelika Kindermann, Marc A. Benninga

Published in: European Journal of Pediatrics | Issue 10/2016

Login to get access

Abstract

In adult inflammatory bowel disease (IBD) patients, there is a strong discrepancy between symptoms and biomarkers of inflammation. Data on pediatric IBD patients are conflicting. Therefore, we aimed to investigate the relationship between clinical symptoms and biomarkers of inflammation in pediatric IBD. Patients aged <18 years with previously diagnosed Crohn’s disease (CD) or ulcerative colitis (UC) were included. Clinical disease activity was determined using the abbreviated Pediatric CD Activity Index (aPCDAI) or Pediatric UC Activity Index (PUCAI). Biochemical disease activity was assessed using fecal calprotectin (FC) and C-reactive protein (CRP). In total, 127 patients (62 male; median age 14.9 years) were included (82 CD, 45 UC). FC correlated weakly with total aPCDAI score (r s = 0.32; 95 % CI 0.12–0.51; p = 0.003) and total PUCAI score (r s = 0.36; 95 % CI 0.07–0.62; p = 0.015). Only aPCDAI components abdominal examination and perirectal disease and PUCAI component activity level had a significant correlation with levels of FC. CRP correlated weakly with total aPCDAI score (r s = 0.28; 95 % CI 0.05–0.46; p = 0.012) and aPCDAI components abdominal examination and activity level. No significant correlation was observed between CRP and total PUCAI score (r s = 0.01; 95 % CI −0.34–0.29; p = 0.961) or individual PUCAI components.
Conclusion: There is a strong discrepancy between clinical symptoms and biomarkers of inflammation in children with IBD.
What is Known:
A substantial proportion of asymptomatic pediatric inflammatory bowel disease (IBD) patients have elevated biomarkers of inflammation.
There is a strong discrepancy between symptoms and biomarkers of inflammation in adults with IBD.
What is New:
Clinical symptoms are only weakly associated with levels of fecal calprotectin and serum C-reactive protein in children and adolescents with previously diagnosed IBD.
Similarly to adult IBD patients, there is a strong discrepancy between clinical symptoms and biomarkers of inflammation in children with IBD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Aomatsu T, Yoden A, Matsumoto K, Kimura E, Inoue K, Andoh A, Tamai H (2011) Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci 56:2372–2377. doi:10.1007/s10620-011-1633-y CrossRefPubMed Aomatsu T, Yoden A, Matsumoto K, Kimura E, Inoue K, Andoh A, Tamai H (2011) Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci 56:2372–2377. doi:10.​1007/​s10620-011-1633-y CrossRefPubMed
2.
go back to reference Belei O, Simedrea I, Ilie R, Daescu C, Tamara M, Militaru A, Brad G (2011) Correlations of fecal calprotectin with clinical and endoscopic scores in inflammatory bowel diseases in children. Jurnalul Pediatrului 14(55–56):18–25 Belei O, Simedrea I, Ilie R, Daescu C, Tamara M, Militaru A, Brad G (2011) Correlations of fecal calprotectin with clinical and endoscopic scores in inflammatory bowel diseases in children. Jurnalul Pediatrului 14(55–56):18–25
3.
go back to reference Bodelier A, de Boer E, Jonkers D, Hameeteman W, Masclee A, Pierik MJ (2011) Monitoring disease activity in IBD: correlation between clinical activity indices and biomarkers. Gastroenterology 140:S–423. doi:10.1016/S0016-5085(11)61737-X Bodelier A, de Boer E, Jonkers D, Hameeteman W, Masclee A, Pierik MJ (2011) Monitoring disease activity in IBD: correlation between clinical activity indices and biomarkers. Gastroenterology 140:S–423. doi:10.​1016/​S0016-5085(11)61737-X
5.
go back to reference Bross DA, Leichtner AM, Zurakowski D, Law T, Bousvaros A (1996) Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn’s disease. J Pediatr Gastroenterol Nutr 23:164–171CrossRefPubMed Bross DA, Leichtner AM, Zurakowski D, Law T, Bousvaros A (1996) Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn’s disease. J Pediatr Gastroenterol Nutr 23:164–171CrossRefPubMed
6.
go back to reference Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, Cosenza L, Staiano A, Troncone R (2008) Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 40:547–553. doi:10.1016/j.dld.2008.01.017 CrossRefPubMed Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, Cosenza L, Staiano A, Troncone R (2008) Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 40:547–553. doi:10.​1016/​j.​dld.​2008.​01.​017 CrossRefPubMed
7.
go back to reference D’Haens GRAM, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rutgeerts P (2012) Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 18:2218–2224. doi:10.1002/ibd.22917 CrossRefPubMed D’Haens GRAM, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rutgeerts P (2012) Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 18:2218–2224. doi:10.​1002/​ibd.​22917 CrossRefPubMed
9.
go back to reference Gerasimidis K, Nikolaou CK, Edwards CA, McGrogan P (2011) Serial fecal calprotectin changes in children with Crohn’s disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol 45:234–239. doi:10.1097/MCG.0b013e3181f39af5 CrossRefPubMed Gerasimidis K, Nikolaou CK, Edwards CA, McGrogan P (2011) Serial fecal calprotectin changes in children with Crohn’s disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol 45:234–239. doi:10.​1097/​MCG.​0b013e3181f39af5​ CrossRefPubMed
10.
go back to reference Hoekman DR, Brandse JF, de Meij TG, Hummel TZ, Löwenberg M, Benninga MA, D’Haens GR, Kindermann A (2015) The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease. Scand J Gastroenterol 50:1110–1117. doi:10.3109/00365521.2015.1027264 CrossRefPubMed Hoekman DR, Brandse JF, de Meij TG, Hummel TZ, Löwenberg M, Benninga MA, D’Haens GR, Kindermann A (2015) The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease. Scand J Gastroenterol 50:1110–1117. doi:10.​3109/​00365521.​2015.​1027264 CrossRefPubMed
12.
go back to reference Kolho KL, Turner D, Veereman-Wauters G, Sladek M, de Ridder L, Shaoul R, Paerregaard A, Amil Dias J, Koletzko S, Nuti F, Bujanover Y, Staiano A, Bochenek K, Finnby L, Levine A, Veres G (2012) Rapid test for fecal calprotectin levels in children with Crohn disease. J Pediatr Gastroenterol Nutr 55:436–439. doi:10.1097/MPG.0b013e318253cff1 CrossRefPubMed Kolho KL, Turner D, Veereman-Wauters G, Sladek M, de Ridder L, Shaoul R, Paerregaard A, Amil Dias J, Koletzko S, Nuti F, Bujanover Y, Staiano A, Bochenek K, Finnby L, Levine A, Veres G (2012) Rapid test for fecal calprotectin levels in children with Crohn disease. J Pediatr Gastroenterol Nutr 55:436–439. doi:10.​1097/​MPG.​0b013e318253cff1​ CrossRefPubMed
13.
go back to reference Komraus M, Wos H, Wiecek S, Kajor M, Grzybowska-Chlebowczyk U (2012) Usefulness of faecal calprotectin measurement in children with various types of inflammatory bowel disease. Mediat Inflamm 2012:608249. doi:10.1155/2012/608249 CrossRef Komraus M, Wos H, Wiecek S, Kajor M, Grzybowska-Chlebowczyk U (2012) Usefulness of faecal calprotectin measurement in children with various types of inflammatory bowel disease. Mediat Inflamm 2012:608249. doi:10.​1155/​2012/​608249 CrossRef
14.
go back to reference Kopylov U, Yablecovitch D, Lahat A, Neuman S, Levhar N, Greener T, Klang E, Rozendorn N, Amitai MM, Ben-Horin S, Eliakim R (2015) Detection of small bowel mucosal healing and deep remission in patients with known small bowel Crohn’s disease using biomarkers, capsule endoscopy, and imaging. Am J Gastroenterol 110:1316–1323. doi:10.1038/ajg.2015.221 CrossRefPubMed Kopylov U, Yablecovitch D, Lahat A, Neuman S, Levhar N, Greener T, Klang E, Rozendorn N, Amitai MM, Ben-Horin S, Eliakim R (2015) Detection of small bowel mucosal healing and deep remission in patients with known small bowel Crohn’s disease using biomarkers, capsule endoscopy, and imaging. Am J Gastroenterol 110:1316–1323. doi:10.​1038/​ajg.​2015.​221 CrossRefPubMed
15.
go back to reference Krzesiek E (2015) Fecal calprotectin as an activity marker of inflammatory bowel disease in children. Adv Clin Exp Med 24:815–822.CrossRefPubMed Krzesiek E (2015) Fecal calprotectin as an activity marker of inflammatory bowel disease in children. Adv Clin Exp Med 24:815–822.CrossRefPubMed
16.
go back to reference Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, Fell J, Ruemmele FM, Walters T, Sherlock M, Dubinsky M, Hyams JS (2011) Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 17:1314–1321. doi:10.1002/ibd.21493 CrossRefPubMed Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, Fell J, Ruemmele FM, Walters T, Sherlock M, Dubinsky M, Hyams JS (2011) Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 17:1314–1321. doi:10.​1002/​ibd.​21493 CrossRefPubMed
17.
go back to reference Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, Kolho K-L, Veres G, Russell RK, Paerregaard A, Buderus S, Greer M-LC, Dias JA, Veereman-Wauters G, Lionetti P, Sladek M, Martin de Carpi J, Staiano A, Ruemmele FM, Wilson DC (2014) ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 58:795–806. doi:10.1097/MPG.0000000000000239 PubMed Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, Kolho K-L, Veres G, Russell RK, Paerregaard A, Buderus S, Greer M-LC, Dias JA, Veereman-Wauters G, Lionetti P, Sladek M, Martin de Carpi J, Staiano A, Ruemmele FM, Wilson DC (2014) ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 58:795–806. doi:10.​1097/​MPG.​0000000000000239​ PubMed
18.
go back to reference Loonen HJ, Griffiths AM, Merkus MP, Derkx HHF (2003) A critical assessment of items on the Pediatric Crohn’s Disease Activity Index. J Pediatr Gastroenterol Nutr 36:90–95CrossRefPubMed Loonen HJ, Griffiths AM, Merkus MP, Derkx HHF (2003) A critical assessment of items on the Pediatric Crohn’s Disease Activity Index. J Pediatr Gastroenterol Nutr 36:90–95CrossRefPubMed
20.
go back to reference Mooiweer E, Severs M, Schipper MEI, Fidder HH, Siersema PD, Laheij RJF, Oldenburg B (2014) Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis 9:50–55. doi:10.1093/ecco-jcc/jju003 CrossRefPubMed Mooiweer E, Severs M, Schipper MEI, Fidder HH, Siersema PD, Laheij RJF, Oldenburg B (2014) Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis 9:50–55. doi:10.​1093/​ecco-jcc/​jju003 CrossRefPubMed
21.
go back to reference Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn WJ, Feagan BG (2015) C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol 110:802–819. doi:10.1038/ajg.2015.120 CrossRefPubMed Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn WJ, Feagan BG (2015) C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol 110:802–819. doi:10.​1038/​ajg.​2015.​120 CrossRefPubMed
22.
go back to reference Munkholm P, Langholz E, Nielsen OH, Kreiner S, Binder V (2009) Incidence and prevalence of Crohn’s disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. Scand J Gastroenterol 27:609–614. doi:10.3109/00365529209000127 CrossRef Munkholm P, Langholz E, Nielsen OH, Kreiner S, Binder V (2009) Incidence and prevalence of Crohn’s disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. Scand J Gastroenterol 27:609–614. doi:10.​3109/​0036552920900012​7 CrossRef
23.
go back to reference Nakarai A, Kato J, Hiraoka S, Inokuchi T, Takei D, Moritou Y, Akita M, Takahashi S, Hori K, Harada K, Okada H, Yamamoto K (2014) Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count. World J Gastroenterol 20:18367–18374. doi:10.3748/wjg.v20.i48.18367 CrossRefPubMedPubMedCentral Nakarai A, Kato J, Hiraoka S, Inokuchi T, Takei D, Moritou Y, Akita M, Takahashi S, Hori K, Harada K, Okada H, Yamamoto K (2014) Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count. World J Gastroenterol 20:18367–18374. doi:10.​3748/​wjg.​v20.​i48.​18367 CrossRefPubMedPubMedCentral
24.
28.
go back to reference Scaioli E, Scagliarini M, Cardamone C, Liverani E, Ugolini G, Festi D, Bazzoli F, Belluzzi A (2015) Clinical application of faecal calprotectin in ulcerative colitis patients. Eur J Gastroenterol Hepatol 27:1418–1424. doi:10.1097/MEG.0000000000000461 PubMed Scaioli E, Scagliarini M, Cardamone C, Liverani E, Ugolini G, Festi D, Bazzoli F, Belluzzi A (2015) Clinical application of faecal calprotectin in ulcerative colitis patients. Eur J Gastroenterol Hepatol 27:1418–1424. doi:10.​1097/​MEG.​0000000000000461​ PubMed
29.
go back to reference Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F (2009) Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 15:1851–1858. doi:10.1002/ibd.20986 CrossRefPubMed Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F (2009) Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 15:1851–1858. doi:10.​1002/​ibd.​20986 CrossRefPubMed
30.
go back to reference Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F (2010) Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s Disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 105:162–169. doi:10.1038/ajg.2009.545 CrossRefPubMed Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F (2010) Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s Disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 105:162–169. doi:10.​1038/​ajg.​2009.​545 CrossRefPubMed
31.
go back to reference Shah SC, Colombel J-F, Sands BE, Narula N (2015) Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Aliment Pharmacol Ther 43:317–333. doi:10.1111/apt.13475 CrossRefPubMed Shah SC, Colombel J-F, Sands BE, Narula N (2015) Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Aliment Pharmacol Ther 43:317–333. doi:10.​1111/​apt.​13475 CrossRefPubMed
32.
go back to reference Shah SC, Colombel J-F, Sands BE, Narula N (2016) Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. doi:10.1016/j.cgh.2016.01.015 Shah SC, Colombel J-F, Sands BE, Narula N (2016) Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. doi:10.​1016/​j.​cgh.​2016.​01.​015
33.
go back to reference Shaoul R, Sladek M, Turner D, Paeregaard A, Veres G, Wauters GV, Escher J, Dias JA, Lionetti P, Staino A, Kolho KL, de Ridder L, Nuti F, Cucchiara S, Sheva O, Levine A (2012) Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn’s disease. Inflamm Bowel Dis 18:1493–1497. doi:10.1002/ibd.21875 CrossRefPubMed Shaoul R, Sladek M, Turner D, Paeregaard A, Veres G, Wauters GV, Escher J, Dias JA, Lionetti P, Staino A, Kolho KL, de Ridder L, Nuti F, Cucchiara S, Sheva O, Levine A (2012) Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn’s disease. Inflamm Bowel Dis 18:1493–1497. doi:10.​1002/​ibd.​21875 CrossRefPubMed
34.
go back to reference Shepanski MA, Markowitz JE, Mamula P, Hurd LB, Baldassano RN (2004) Is an abbreviated Pediatric Crohn’s Disease Activity Index better than the original? J Pediatr Gastroenterol Nutr 39:68–72CrossRefPubMed Shepanski MA, Markowitz JE, Mamula P, Hurd LB, Baldassano RN (2004) Is an abbreviated Pediatric Crohn’s Disease Activity Index better than the original? J Pediatr Gastroenterol Nutr 39:68–72CrossRefPubMed
36.
go back to reference Sipponen T, Savilahti E, Kolho K-L, Nuutinen H, Turunen U, Färkkilä M (2008) Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 14:40–46. doi:10.1002/ibd.20312 CrossRefPubMed Sipponen T, Savilahti E, Kolho K-L, Nuutinen H, Turunen U, Färkkilä M (2008) Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 14:40–46. doi:10.​1002/​ibd.​20312 CrossRefPubMed
37.
go back to reference Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, Walters TD, Zachos M, Mamula P, Beaton DE, Steinhart AH, Griffiths AM (2007) Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 133:423–432. doi:10.1053/j.gastro.2007.05.029 CrossRefPubMed Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, Walters TD, Zachos M, Mamula P, Beaton DE, Steinhart AH, Griffiths AM (2007) Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 133:423–432. doi:10.​1053/​j.​gastro.​2007.​05.​029 CrossRefPubMed
39.
go back to reference Voiosu T, Benguş A, Dinu R, Voiosu AM, Bălănescu P, Băicuş C, Diculescu M, Voiosu R, Mateescu B (2014) Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study. J Gastrointestin Liver Dis 23:273–278PubMed Voiosu T, Benguş A, Dinu R, Voiosu AM, Bălănescu P, Băicuş C, Diculescu M, Voiosu R, Mateescu B (2014) Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study. J Gastrointestin Liver Dis 23:273–278PubMed
41.
go back to reference Yamaguchi S, Takeuchi Y, Arai K, Fukuda K, Kuroki Y, Asonuma K, Takahashi H, Saruta M, Yoshida H (2015) Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis. J Gastroenterol Hepatol 31:93–98. doi:10.1111/jgh.13061 CrossRef Yamaguchi S, Takeuchi Y, Arai K, Fukuda K, Kuroki Y, Asonuma K, Takahashi H, Saruta M, Yoshida H (2015) Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis. J Gastroenterol Hepatol 31:93–98. doi:10.​1111/​jgh.​13061 CrossRef
42.
go back to reference Yoo S, Jung YS, Park JH, Kim HJ, Cho YK, Sohn C II, Jeon WK, Kim BI, Park D II (2014) Fatigue severity and factors associated with high fatigue levels in Korean patients with inflammatory bowel disease. Gut Liver 8:148–153. doi:10.5009/gnl.2014.8.2.148 CrossRefPubMed Yoo S, Jung YS, Park JH, Kim HJ, Cho YK, Sohn C II, Jeon WK, Kim BI, Park D II (2014) Fatigue severity and factors associated with high fatigue levels in Korean patients with inflammatory bowel disease. Gut Liver 8:148–153. doi:10.​5009/​gnl.​2014.​8.​2.​148 CrossRefPubMed
Metadata
Title
Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease
Authors
Daniël R. Hoekman
Kay Diederen
Bart G. P. Koot
Merit M. Tabbers
Angelika Kindermann
Marc A. Benninga
Publication date
01-10-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Pediatrics / Issue 10/2016
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-016-2762-2

Other articles of this Issue 10/2016

European Journal of Pediatrics 10/2016 Go to the issue